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Abstract 
Introduction: Although atherosclerotic disease cannot be cured, risk of recur-
rent events can be reduced by application of evidence-based treatment proto-
cols involving aspirin, beta blockers, angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers, and statin medications. We studied athero-
sclerotic event rates in a patient population treated before and after the devel-
opment of aggressive risk factor reduction treatment protocols.
Material and methods: We performed a retrospective chart review of patients
presenting for follow-up treatment of coronary artery disease in a community
cardiology practice, comparing atherosclerotic event rates and medication usage
in a 2-year treatment period prior to 2002 and a 2-year period in 2005-2008.
Care was provided in both the early and later eras by 7 board-certified cardiol-
ogists in a suburban cardiology practice. Medication usage was compared in
both treatment eras. The primary outcome was a composite event rate of
myocardial infarction, cerebrovascular events, and coronary interventions. 
Results: Three hundred and fifty-seven patients were studied, with a follow-up
duration of 12.1 (±3.5) years. There were 132 composite events in 104 patients
(29.1%) in the early era compared to 40 events in 33 patients (9.2%) in the lat-
er era (p < 0.0001). From the early to the later eras, there was an increase in
use of β-blockers (66% to 83%, p < 0.0001), angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers (34% to 80%, p < 0.0001), and statins
(40% to 90%, p < 0.0001).
Conclusions: Application of aggressive evidence-based medication protocols for
treatment of atherosclerosis is associated with a significant decrease in ather-
osclerotic events or need for coronary intervention.
Key words: atherosclerosis, myocardial infarction, cerebrovascular events, cardio-
vascular drugs.
Introduction
While mortality statistics still point to coronary heart disease as the
number one killer in the United States [1], many cardiologists have per-
ceived a dramatic change in this disease over the last 20 years, with reduc-
tions in incidence and severity noted by community physicians in clinical
practice. In our practice of 7 cardiologists in a suburban New York City
community, we noticed that the incidence of myocardial infarction and
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need for percutaneous coronary intervention and
coronary artery bypass surgery seemed to be
decreasing in recent years compared with time peri-
ods prior to the late 1990s. Since use of statin med-
ications and angiotensin-converting enzyme (ACE)
inhibitors increased during the late 1990s and ear-
ly 2000s, we hypothesized that the decrease in inci-
dence of coronary heart disease events we were
seeing was due to newer and more aggressive
treatment regimens for outpatients, especially in
secondary prevention. Multicenter studies have
shown that aspirin, β-blockers, ACE inhibitors, and
statin medications can be used to reduce the risk
of coronary events. We decided to test our hypoth-
esis in our own patient population by performing
a retrospective review of patient charts to deter-
mine whether changes in medical therapy were
associated with a decrease in the incidence of
myocardial infarction and need for coronary inter-
ventions.
Material and methods
We examined paper and electronic chart records
of 1770 randomly selected patients who presented
to our outpatient cardiology practice in 2003-2006,
and carried a diagnosis of coronary artery disease.
We identified 357 patients in that group who ini-
tially presented with symptoms or signs of coro-
nary artery disease before January 1, 2000 and were
treated continuously through 2005-2008. For each
patient, we looked at progress notes of all interim
office visits and recorded medication usage, blood
pressure, laboratory studies including lipid levels,
and occurrence of adverse cardiovascular events
from the time of initial presentation to last follow-
up. Adverse events included occurrence of acute
myocardial infarction or stroke, or need for coro-
nary intervention, either percutaneous or surgical.
We compared the earliest 2-year periods for each
patient during the first era, to the latest 2-year peri-
od of follow-up in the second era. A total of 1748 vi  -
sits in those 2 two-year periods were abstracted. If
a patient presented initially with an adverse car-
diovascular event, that event was not included as
an event in the early era. For baseline data collec-
tion, comorbidities of coronary artery disease,
hyperlipidemia, diabetes mellitus, hypertension,
congestive heart failure, angina, atrial fibrillation,
carotid stenosis, transient ischemic attack, cere-
brovascular accident, chronic kidney disease, ciga-
rette smoking history, peripheral vascular disease,
abdominal aortic aneurysm, and previous coronary
event or intervention were recorded. Occurrence 
of subsequent myocardial infarction, transient
ischemic attack, or cerebrovascular accident was
recorded, as well as requirement for percutaneous
coronary intervention or coronary artery bypass
grafting. Dates of the events as well as dates of all
medication initiation and discontinuation were
recorded. Coronary artery disease was diagnosed
as previously described [2-5]. Cerebrovascular acci-
dent was diagnosed as previously described [6-8].
The data were extracted from paper and elec-
tronic charts by the physician authors. Data collec-
tion was tabulated with Microsoft Access 2003, and
statistical analysis was performed in Microsoft Excel
2003 (Microsoft Corporation, Redmond, WA, USA).
Paired t-testing was used to analyze for statistical
significance. A p-value of < 0.05 was considered
statistically significant. 
Results
Demographics and associated clinical charac-
teristics are shown in Tables I and II. The group con-
sisted of 246 males (69%) and 111 females. Average
age at the time of the first visit was 62.7 ±10.8 years
and at the last visit was 74.7 ±10.6 years. All
patients had evidence for coronary artery disease
at the time of presentation (angina, positive stress
test, coronary artery disease on cardiac catheteri-
zation, or prior history of myocardial infarction, per-
cutaneous coronary intervention (PCI), or coronary
artery bypass surgery (CABS)). Other comorbidities
included hyperlipidemia in 322 (90%) of the
patients, diabetes in 80 (22%), hypertension in 295
(83%), congestive heart failure in 58 (16%), angina
in 47 (13%), and atrial fibrillation in 69 (19%). One
hundred and fifty-six (44%) of the patients were
smokers. Other comorbidities are shown in Table II.
The primary endpoint of the study was a com-
posite of myocardial infarction, cerebrovascular
event (transient ischemic attack or stroke), or
requirement for coronary intervention (either PCI
or CABS).
One hundred and thirty-five (37.8%) of the
patients had myocardial infarction prior to (126
patients) or at their first visit, 67 (18.8%) had PCI
prior to (62 patients) or at their first visit, 59 (16.5%)
had CABS prior to (55 patients) or at their first vis-
it, 4 patients had transient ischemic attack prior to
(3 patients) or at their first visit, and 8 patients had
history of cerebrovascular accident prior to their
first visit. Only events or interventions that occurred
Number of patients 357
Age at first date of therapy [years] 62.7 ±10.8
Age at second era [years] 74.7 ±10.6
Men 246 (69%)
Women 111 (31%)
Duration of follow-up [years] 12.1 ±3.5
Year range for early era 1977-2001
Year range for later era 2003-2008
Table I. Characteristics of patients and study erasArch Med Sci 1, February / 2012 59
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after the first visit in the early era were counted as
an event in that era. The early follow-up era con-
sisted of 2-year periods which were completed
before December 31, 2001 (range of start dates from
March 3, 1977 to December 27, 1999). The later fol-
low-up era consisted of 2 year periods which were
completed before November 7, 2008 (range of start
dates September 21, 2003 to November 6, 2006). 
The composite endpoint of myocardial infarction,
cerebrovascular event (transient ischemic attack or
stroke), and requirement for coronary intervention
was significantly reduced in the later follow-up era
compared to the early follow-up era (Table III, 
Figure 1). The need for CABS and PCI decreased
from the early era to the later era. Percutaneous
coronary interventions decreased from 63 inter-
ventions in 50 patients (14%) in the early era to 
17 interventions in 16 patients (4.5%) in the later
era (p < 0.0001). Requirement for CABS decreased
from 53 procedures in 53 patients (14.8%) in the
early era to 8 procedures in 8 patients (2.2%) in the
later era (p < 0.0001). Five patients of 50 who
underwent PCI in the early era required CABS in the
early era, and 2 required CABS in the later era. Three
patients who had a PCI in the early era required
a repeat PCI in the later era. Only 1 patient of 53
who had a CABS in the early era required a CABS
in the later era. In the early era, 9 patients (2.5%)
experienced a total of 10 myocardial infarctions,
while in the later era, 5 patients (1.4%) experienced
myocardial infarctions, a result that was not sta-
tistically significant. Incidences of transient ischemic
attack and cerebrovascular accident were also sta-
tistically un  changed. Of note, 4 of the 5 patients
(80%) who experienced a myocardial infarction in
the later era were not on statin medications.
Medication treatment regimens during these 2
follow-up periods changed significantly (Table IV).
Statin use increased between the early era and the
later era from 142 patients (39.8%) to 323 patients
(90.5%, p < 0.0001). β-Blocker use increased from
235 patients (65.8%) to 295 patients (82.6%, 
p < 0.0001). Angiotensin converting enzyme inhi  b  -
itor use increased from 101 patients in the early 
era (28.3%) to 216 in the later era (60.5%, 
p < 0.0001). Use of angiotensin receptor blockers
also increased from 25 patients (7.0%) in the early
era to 98 (27.5%, p < 0.0001) in the later.
Therefore, use of either ACE inhibitors or
angiotensin receptor blockers increased from 34%
to 80%. Although use of ezetimibe also increased
from none in the early era to 100 patients (28.0%)
in the later era, all but 3 of these patients were
placed on ezetimibe together with a statin med-
ication. Aspirin and calcium channel blocker use did
not change. Use of other agents also increased
(clopidogrel, warfarin, insulin, thiazolidinediones,
Comorbidity n (%)
Coronary artery disease 357 (100)
Hyperlipidemia 322 (90)
Diabetes mellitus 80 (22)
Hypertension 295 (83)
Clinical congestive heart failure 58 (16)
Angina 47 (13)
Atrial fibrillation 69 (19)
Carotid stenosis 19 (5)
Transient ischemic attack 22 (6)
Cerebrovascular accident 39 (11)
Chronic kidney disease 10 (3)
Smoker at time of presentation 156 (44)
Peripheral vascular disease 40 (11)
Aortic abdominal aneurysm 16 (4)
Prior myocardial infarction 135 (38)
Prior percutaneous coronary intervention 67 (19)
Prior coronary artery bypass surgery 59 (17)
Prior transient ischemic attack 4 (1)
Prior cerebrovascular accident 8 (2)
Table II. Associated clinical characteristics and comor-
bidities of patients in the study
Outcomes Early era Later era Value of p
Adverse  Patients with  Adverse  Patients with 
events, n adverse events, n (%) events, n adverse events, n (%)
MI 10 9 (2.5) 5 5 (1.4) 0.29
PCI 63 50 (14.0) 17 16 (4.5) < 0.001
CABS 53 53 (14.8) 8 8 (2.2) < 0.001
TIA 2 2 (0.6) 1 1 (0.3) 0.56
CVA 4 4 (1.1) 9 8 (2.2) 0.25
Composite 132 104 (29.1) 40 33 (9.2) < 0.001
Table III. Outcomes in the patient group in the early era vs. later era
MI – myocardial infarction, PCI – percutaneous coronary intervention, CABS – coronary artery bypass surgery, TIA – transient ischemic attack,
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and metformin), but these drugs were used in only
a small percentage of the patients in both eras.
Clopidogrel was used with aspirin in all but 2 pa  -
tients in the early era, and in all but 8 patients in
the later era. Use of long-acting nitrates declined
from 30% to 18%.
Discussion
Coronary atherosclerosis is still a major cause of
morbidity and mortality in the United States pop-
ulation, but our data shows that with aggressive
treatment using evidence-based protocols, even
patients with overt coronary artery disease can
reduce their chance of developing subsequent
events or requirement for interventions. Peroxisome
proliferator-activated receptor-gamma and retinoid
X receptor-α expression down-regulation in both
macrophages and smooth muscle cells was associ-
ated with more pronounced disease progression in
patients with advanced carotid atherosclerotic
lesions [9]. Further studies need to be performed
to investigate the value of modulating vitamin D
signaling [10], using serotonin reuptake inhibitor
antidepressants [11], and postprandial use of ver-
juice [12] in treatment of atherosclerosis.
The patients in this trial acted as their own con-
trols, and although the group had a high prevalence
of angina, myocardial infarction, positive stress
tests, and need for coronary intervention prior to
the year 2002, their chance of requiring coronary
intervention decreased in later years, and incidence
of myocardial infarction did not increase. Since coro-
nary atherosclerosis is a progressive disease
process, one would expect the incidence of events
to increase over time; the opposite happened to
the patients in this study, and the most likely rea-
son is use of more aggressive preventive treatment
protocols. This study shows that such aggressive
therapies can be implemented successfully in
a community cardiology practice. For the most part,
these protocols involve medications such as statins,
ACE inhibitors (and to a lesser extent angiotensin
receptor blockers), aspirin, and β-blockers. While
the use of aspirin did not increase significantly,
there was a high rate of use of aspirin in both
groups, and the use of clopidogrel increased sig-
nificantly during this time.
Numerous studies have shown the benefits of
statin drugs [13-15], ACE inhibitor [16-18], β-block-
ers [19-21], and aspirin [22, 23] for reducing events
in patients with documented coronary artery dis-
ease, but there are little data examining the appli-
cation of these evidence-based protocols in com-
munity clinical practice and over long periods of
time. A randomized, blinded trial to investigate the
application of these protocols in community prac-
tice is not possible for ethical reasons. Although this
study is a retrospective analysis, it provides pre-
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Figure 1. Percent of patients with events in early era
and later era
MI – myocardial infarction, PCI – percutaneous coronary inter-
vention, CABG – coronary artery bypass grafting
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Medications Earlier era Later era Value of p
n (%) n (%)
Statins 142 (40) 323 (90) < 0.001
Ezetimibe 0 (0) 100 (28) < 0.001
Nicotinic acid 11 (3) 13 (4) 0.67
Bile acid  2 (1) 1 (0.3) 0.56
sequestrants
Fibrates 17 (5) 18 (5) 0.84
Fish oils 2 (1) 22 (6) < 0.001
β-Blockers 235 (66) 295 (83) < 0.001
Diuretics 115 (32) 202 (57) < 0.001
ACE-I 101 (28) 216 (61) < 0.001
ARB 25 (7) 98 (27) < 0.001
ACE-I or ARB 123 (34) 285 (80) < 0.001
Calcium channel  161 (45) 148 (41) 0.24
blocker
Aspirin 278 (78) 282 (79) 0.67
Ticlopidine 17 (5) 0 (0) < 0.001
Clopidogrel 18 (5) 62 (17) < 0.001
Aspirin/ 1 (0.3) 7 (2) 0.03
extended-release 
dipyridamole
Warfarin 50 (14) 95 (27) < 0.001
Nitrates 108 (30) 64 (18) < 0.001
Digoxin 56 (16) 64 (18) 0.29
Cilostazol 0 (0) 6 (2) 0.01
Insulin 15 (4) 30 (8) < 0.001
Thiazolidinediones 8 (2) 38 (11) < 0.001
Sulfonylureas 32 (9) 49 (14) 0.006
Metformin 20 (6) 48 (13) < 0.001
Sitagliptin 0 (0) 2 (1) 0.16
ACE-I – angiotensin converting enzyme inhibitors, ARB – angiotensin
receptor blockers
Table IV. Medication use for at least one visit in the
earlier and later erasArch Med Sci 1, February / 2012 61
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sumptive data that changes in the practice of treat-
ing coronary disease over the past 20 years have
significantly reduced event rates and the need for
coronary interventions in this population.
Other possible contributing factors to the reduc-
tion in events include improved coronary interven-
tion (CABS and PCI) and lifestyle changes. Howev-
er, even patients without interventions in the early
era had no increase in the need for interventions
in the later era. It is also unlikely that improved
interventional techniques resulted in reduced need
for repeat procedures, since only 6 patients who
had PCI or CABS in the first era required a second
procedure in the later era. While the physicians in
our practice recommend lifestyle changes strongly
to our patients, it is our experience that many
patients do not follow these changes, and that
many who do cannot maintain them over long peri-
ods of time; unfortunately, compliance with lifestyle
changes is difficult to measure and quantify. 
There are limitations to a retrospective study
such as this one. Patients were not randomized to
treatment protocols, but this study more closely
mimics actual clinical treatment among communi-
ty-based cardiologists. Adherence to medication
treatment could not be determined, since tech-
niques such as pill counts were not employed, but
it is our experience that our patient population
tends to follow medication regimens. Mortality dif-
ferences were not examined in this study since the
criteria for entry was attendance at the later era
visit. It is possible that very sick patients who were
seen in the early era could have died before they
would have presented for follow-up in the later era.
A part of benefit, possibly small, should be attrib-
uted to this factor.
This retrospective study should give communi-
ty practitioners, both specialists and primary care
providers, the encouragement to pursue aggressive
cardiovascular risk reduction strategies as a means
for reducing the need for cardiovascular procedures
in their patients. More importantly, it provides
patients with the knowledge that, while coronary
artery disease cannot be cured, there is hope that
with proper and aggressive risk factor reduction
therapies it can be controlled.
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